内分泌治疗用于乳腺癌已有100多年的历史,具有疗效确实、耐受性良好的特点,已在各期激素受体阳性乳腺癌的辅助治疗中占据重要地位。目前,三苯氧胺仍是绝经前患者的标准用药,绝经后患者则首选芳香化酶抑制剂。本文就近年来进行的多个大宗临床试验,对乳腺癌内分泌治疗研究进展做一综述。 Endocrine therapy for breast cancer has more than 100 years of history, with a curative effect, well tolerated features, has been in various stages of adjuvant hormone receptor-positive breast cancer occupy an important position. At present, tamoxifen is still the standard medication in premenopausal patients, and preferred aromatase inhibitors in postmenopausal patients. In this paper, a number of large-scale clinical trials conducted in recent years, the progress of breast cancer endocrine therapy are reviewed.